Centro Hospitalar Universitario De Santo Antonio E.P.E.

Verifiedinfo

Portugal Largo Professor Abel Salazar, 4050-011 Porto, Portugal

67 trials recruiting
Non-small cell lung cancer · Dermatitis atopic · Pulmonary arterial hypertension
Adults and children

About Specializations

Centro Hospitalar Universitario De Santo Antonio E.P.E. in Porto, Portugal specialises in clinical trials of conditions such as Non-small cell lung cancer, Dermatitis atopic, Pulmonary arterial hypertension, Crohn's disease, and other specialisations. This site conducts important research.

Main research areas of the site

Nervous System Diseases

The Centro Hospitalar Universitario De Santo Antonio pediatric neurology team is studying Migraine in children, testing a new biologic therapy to reduce the number of migraine days and improve daily functioning.

Evaluation of a novel preventive treatment
Assessment of attack frequency reduction
Monitoring safety and tolerability in young patients
Impact on quality of life and school attendance
Long‑term follow‑up of therapeutic outcomes

With 73 investigators involved, the site in Porto, Portugal, is leading five independent trials aimed at advancing care for pediatric migraine sufferers.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Largo Professor Abel Salazar4050-011 PortoPortugal

Open in maps ↗

Recruiting now: 67 trials
Conditions studied: 130
Partner status: Verified

More sites in Porto Portugal

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

174 clinical trials

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Recruiting

Investigational

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational

Portugal

Participants:18–64 years
Sponsor:Zenas Biopharma (USA) LLC

Contact Research Centre

Primary progressive multiple sclerosis

Recruiting

Investigational

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational

Portugal

Participants:18–64 years
Sponsor:Zenas Biopharma (USA) LLC

Contact Research Centre

Focal segmental glomerulosclerosis

Recruiting

Investigational

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational

Portugal

Participants:0–17 years · 18–64 years · 65+ years
Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
Sponsor:Boehringer Ingelheim Espana S.A.